Proteomic analysis of the cerebrospinal fluid of patients with restless legs syndrome/Willis-Ekbom disease

Fluids and Barriers of the CNS

Volumn 10, Issue 1, 2013, Pages

  Patton, Stephanie M ^a   Cho, Yong Won ^b   Clardy, Thomas W ^a   Allen, Richard P ^c   Earley, Christopher J ^c   Connor, James R ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b Dongsan Medical Center   (South Korea)

^c JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

Hypoxia inducible factor; Nitric oxide; Pain; Restless legs syndrome Willis Ekbom disease; Sleep disorders

Indexed keywords

APOLIPOPROTEIN A; CYSTATIN C; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR; LIPOCALIN 1; PROSTAGLANDIN SYNTHASE; VITAMIN D;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GEL ELECTROPHORESIS; HUMAN; IMMUNOBLOTTING; LUMBAR PUNCTURE; PAIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; RESTLESS LEGS SYNDROME; SENSORIMOTOR NEUROPATHY; STUDENT T TEST; VALIDATION STUDY; WILIS EKBOM DISEASE;

EID: 84878647787     PISSN: None     EISSN: 20458118     Source Type: Journal    
DOI: 10.1186/2045-8118-10-20     Document Type: Article

References (47)

1. Allen RP, Walters AS, Montplaisir J, Hening W, Myers A, Bell TJ, Ferini-Strambi L. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005, 165:1286-1292. 10.1001/archinte.165.11.1286, 15956009.
2. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003, 4:101-119. 10.1016/S1389-9457(03)00010-8, 14592341.
3. Earley CJ, Silber MH. Restless legs syndrome: understanding its consequences and the need for better treatment. Sleep Med 2010, 11:807-815. 10.1016/j.sleep.2010.07.007, 20817595.
4. Ulfberg J, Nystrom B, Carter N, Edling C. Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms. Mov Disord 2001, 16:1159-1163. 10.1002/mds.1209, 11748753.
5. Winkelman JW, Finn L, Young T. Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort. Sleep Med 2006, 7:545-552. 10.1016/j.sleep.2006.01.004, 16740407.
6. Winkelman JW, Shahar E, Sharief I, Gottlieb DJ. Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study. Neurology 2008, 70:35-42. 10.1212/01.wnl.0000287072.93277.c9, 18166705.
7. Ohayon MM, Roth T. Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. J Psychosom Res 2002, 53:547-554. 10.1016/S0022-3999(02)00443-9, 12127170.
8. Allen RP, Earley CJ. The role of iron in restless legs syndrome. Mov Disord 2007, 22(Suppl 18):S440-S448.
9. Allen RP, Barker PB, Wehrl F, Song HK, Earley CJ. MRI measurement of brain iron in patients with restless legs syndrome. Neurology 2001, 56:263-265. 10.1212/WNL.56.2.263, 11160969.
10. Godau J, Klose U, Di Santo A, Schweitzer K, Berg D. Multiregional brain iron deficiency in restless legs syndrome. Mov Disord 2008, 23:1184-1187. 10.1002/mds.22070, 18442125.
11. Cho YW, Shin WC, Yun CH, Hong SB, Kim JH, Allen RP, Earley CJ. Epidemiology of restless legs syndrome in Korean adults. Sleep 2008, 31:219-223. 2225579, 18274269.
12. Hening WA, Allen RP, Washburn M, Lesage S, Earley CJ. Validation of the Hopkins telephone diagnostic interview for restless legs syndrome. Sleep Med 2008, 9:283-289. 10.1016/j.sleep.2007.04.021, 17644424.
13. Geguchadze RN, Coe CL, Lubach GR, Clardy TW, Beard JL, Connor JR. CSF proteomic analysis reveals persistent iron deficiency-induced alterations in non-human primate infants. J Neurochem 2008, 105:127-136. 10.1111/j.1471-4159.2007.05113.x, 17996030.
14. Connor JR, Wang XS, Patton SM, Menzies SL, Troncoso JC, Earley CJ, Allen RP. Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. Neurology 2004, 62:1563-1567. 10.1212/01.WNL.0000123251.60485.AC, 15136682.
15. Earley CJ, Connor JR, Beard JL, Clardy SL, Allen RP. Ferritin levels in the cerebrospinal fluid and restless legs syndrome: effects of different clinical phenotypes. Sleep 2005, 28:1069-1075.
16. Allen RP, Connor JR, Hyland K, Earley CJ. Abnormally increased CSF 3-Ortho-methyldopa (3-OMD) in untreated restless legs syndrome (RLS) patients indicates more severe disease and possibly abnormally increased dopamine synthesis. Sleep Med 2009, 10:123-128. 10.1016/j.sleep.2007.11.012, 2655320, 18226951.
17. Liu XD, Zeng BF, Xu JG, Zhu HB, Xia QC. Proteomic analysis of the cerebrospinal fluid of patients with lumbar disk herniation. Proteomics 2006, 6:1019-1028. 10.1002/pmic.200500247, 16372267.
18. Mannes AJ, Martin BM, Yang HY, Keller JM, Lewin S, Gaiser RR, Iadarola MJ. Cystatin C as a cerebrospinal fluid biomarker for pain in humans. Pain 2003, 102:251-256. 10.1016/S0304-3959(02)00403-7, 12670666.
19. Abetz L, Allen R, Follet A, Washburn T, Earley C, Kirsch J, Knight H. Evaluating the quality of life of patients with restless legs syndrome. Clin Ther 2004, 26:925-935. 10.1016/S0149-2918(04)90136-1, 15262463.
20. Edwards RR, Quartana PJ, Allen RP, Greenbaum S, Earley CJ, Smith MT. Alterations in pain responses in treated and untreated patients with restless legs syndrome: associations with sleep disruption. Sleep Med 2011, 12:603-609. 10.1016/j.sleep.2010.09.018, 3433041, 21570347.
21. Yunus MB. Role of central sensitization in symptoms beyond muscle pain, and the evaluation of a patient with widespread pain. Best Pract Res Clin Rheumatol 2007, 21:481-497. 10.1016/j.berh.2007.03.006, 17602995.
22. D'Onofrio F, Bussone G, Cologno D, Petretta V, Buzzi MG, Tedeschi G, Bonavita V, Cicarelli G. Restless legs syndrome and primary headaches: a clinical study. Neurol Sci 2008, 29(Suppl 1):S169-S172.
23. Weinstock LB, Walters AS, Paueksakon P. Restless legs syndrome-theoretical roles of inflammatory and immune mechanisms. Sleep Med Rev 2012, 16:341-354. 10.1016/j.smrv.2011.09.003, 22258033.
24. Jordan W, Tumani H, Cohrs S, Eggert S, Rodenbeck A, Brunner E, Ruther E, Hajak G. Prostaglandin D synthase (beta-trace) in healthy human sleep. Sleep 2004, 27:867-874.
25. Jordan W, Hagedohm J, Wiltfang J, Laier-Groeneveld G, Tumani H, Rodenbeck A, Ruther E, Hajak G. Biochemical markers of cerebrovascular injury in sleep apnoea syndrome. Eur Respir J 2002, 20:158-164. 10.1183/09031936.02.00862001, 12166564.
26. Barcelo A, de la Pena M, Barbe F, Pierola J, Bosch M, Agusti AG. Prostaglandin D synthase (beta trace) levels in sleep apnea patients with and without sleepiness. Sleep Med 2007, 8:509-511. 10.1016/j.sleep.2006.10.005, 17512779.
27. Patton SM, Ponnuru P, Snyder AM, Podskalny GD, Connor JR. Hypoxia-inducible factor pathway activation in restless legs syndrome patients. Eur J Neurol 2011, 18:1329-1335. 10.1111/j.1468-1331.2011.03397.x, 21985026.
28. Speeckaert M, Huang G, Delanghe JR, Taes YE. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta 2006, 372:33-42. 10.1016/j.cca.2006.03.011, 16697362.
29. Gomme PT, Bertolini J. Therapeutic potential of vitamin D-binding protein. Trends Biotechnol 2004, 22:340-345. 10.1016/j.tibtech.2004.05.001, 15245906.
30. Qin Z, Qin Y, Liu S. Alteration of DBP levels in CSF of patients with MS by proteomics analysis. Cell Mol Neurobiol 2009, 29:203-210. 10.1007/s10571-008-9312-z, 18807170.
31. Zhang J, Sokal I, Peskind ER, Quinn JF, Jankovic J, Kenney C, Chung KA, Millard SP, Nutt JG, Montine TJ. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol 2008, 129:526-529. 10.1309/W01Y0B808EMEH12L, 2688655, 18343778.
32. Baksi SN, Hughes MJ. Chronic vitamin D deficiency in the weanling rat alters catecholamine metabolism in the cortex. Brain Res 1982, 242:387-390. 10.1016/0006-8993(82)90331-6, 6288172.
33. Masuhara T, Migicovsky BB. Vitamin D and the intestinal absorption of iron and cobalt. J Nutr 1963, 80:332-336.
34. Balaban H, Yildiz OK, Cil G, Senturk IA, Erselcan T, Bolayir E, Topaktas S. Serum 25-hydroxyvitamin D levels in restless legs syndrome patients. Sleep Med 2012, 13:953-957. 10.1016/j.sleep.2012.04.009, 22704399.
35. Biagioli M, Pinto M, Cesselli D, Zaninello M, Lazarevic D, Roncaglia P, Simone R, Vlachouli C, Plessy C, Bertin N, et al. Unexpected expression of alpha- and beta-globin in mesencephalic dopaminergic neurons and glial cells. Proc Natl Acad Sci USA 2009, 106:15454-15459. 10.1073/pnas.0813216106, 2732704, 19717439.
36. Turjanski N, Lees AJ, Brooks DJ. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology 1999, 52:932-937. 10.1212/WNL.52.5.932, 10102408.
37. Cervenka S, Palhagen SE, Comley RA, Panagiotidis G, Cselenyi Z, Matthews JC, Lai RY, Halldin C, Farde L. Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. Brain 2006, 129:2017-2028. 10.1093/brain/awl163, 16816393.
38. Kim KW, Jhoo JH, Lee SB, Lee SD, Kim TH, Kim SE, Kim YK, Yoon IY. Increased striatal dopamine transporter density in moderately severe old restless legs syndrome patients. Eur J Neurol 2012, 19:1213-1218. 10.1111/j.1468-1331.2012.03705.x, 22435397.
39. Koch S, Donarski N, Goetze K, Kreckel M, Stuerenburg HJ, Buhmann C, Beisiegel U. Characterization of four lipoprotein classes in human cerebrospinal fluid. J Lipid Res 2001, 42:1143-1151.
40. Winter AC, Berger K, Glynn RJ, Buring JE, Gaziano JM, Schurks M, Kurth T. Vascular risk factors, cardiovascular disease, and restless legs syndrome in men. Am J Med 2013, 126:228-235 e222. 10.1016/j.amjmed.2012.06.039, 23410563.
41. Schlesinger I, Erikh I, Avizohar O, Sprecher E, Yarnitsky D. Cardiovascular risk factors in restless legs syndrome. Mov Disord 2009, 24:1587-1592. 10.1002/mds.22486, 19526583.
42. Chen GL, Liu LW, Xie S, Liu H, Liu YQ, Li YS. High-density lipoprotein associated factors apoA-I and serum amyloid A in Chinese non-diabetic patients with coronary heart disease. Chin Med J (Engl) 2010, 123:658-663.
43. Moshage H. Cytokines and the hepatic acute phase response. J Pathol 1997, 181:257-266. 10.1002/(SICI)1096-9896(199703)181:3<257::AID-PATH756>3.0.CO;2-U, 9155709.
44. Berger T, Togawa A, Duncan GS, Elia AJ, You-Ten A, Wakeham A, Fong HE, Cheung CC, Mak TW. Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc Natl Acad Sci USA 2006, 103:1834-1839. 10.1073/pnas.0510847103, 1413671, 16446425.
45. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, Akira S, Aderem A. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004, 432:917-921. 10.1038/nature03104, 15531878.
46. Mizuno S, Mihara T, Miyaoka T, Inagaki T, Horiguchi J. CSF iron, ferritin and transferrin levels in restless legs syndrome. J Sleep Res 2005, 14:43-47. 10.1111/j.1365-2869.2004.00403.x, 15743333.
47. Connor JR, Boyer PJ, Menzies SL, Dellinger B, Allen RP, Ondo WG, Earley CJ. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 2003, 61:304-309. 10.1212/01.WNL.0000078887.16593.12, 12913188.